SAN DIEGO, Sept. 29, 2017 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis
company in the United States, today announced that portfolio company KannaLife Sciences' new spokesman Nick Lowery and
former Kansas City Chiefs placekicker, generated a massive amount of media coverage across the United
States about the dangers of chronic traumatic encephalopathy (CTE).
CTE is a degenerative neurological disease caused by repeated head trauma and only diagnosable with certainty in post-mortem
examinations and can lead to symptoms like violent mood swings, depression and other cognitive difficulties. Because there is not
much known about this debilitating disease, treatment and prevention options are bleak.
A September 26, 2017 interview with Fox Business' Varney & Co .
, discussed current research on the diagnosis and treatment of CTE, and its relationship to professional sports
organizations such as the NFL. Lowery also interviewed with CBS show Tiki and
Tierney , where he discussed the applications of CTE prevention to other cases outside of the NFL, such as patients involved
in traumatic car accidents. This was an interview that host Tierney described as "one of the most important interviews we've had
on the show."
"It's encouraging to see the widespread national discussion about CTE research and treatment. We are always proud to be at the
forefront of groundbreaking news that has the capacity to positively impact the world. A goal of our company has been to provide
an alternative health-and-wellness awareness to the largest audience possible," said CEO of Medical Marijuana, Inc. Dr.
Stuart Titus. "We are thrilled to have Nick Lowery on board as
spokesperson for Kannalife Sciences. Nick brings real world experience to our CTE efforts as well as incredible passion to find a
solution for many ex-athletes who are suffering in the later stages of life."
Additionally, Nick discussed the topic of CTE with these other media outlets:
About KannaLife Sciences
Kannalife Sciences, Inc. is a bio-pharmaceutical and phyto-medical company involved in the research and development of novel
new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. Kannalife Sciences
currently holds an exclusive license with National Institutes of Health – Office of Technology Transfer ("NIH-OTT") for the Commercialization of U.S. Patent #6630507, "Cannabinoids as Antioxidants and Neuroprotectants " (the "'507 Patent"). Kannalife is currently
conducting research and development at the Bucks County Pennsylvania Biotechnology Center in Doylestown, PA, for a target drug candidate to treat Hepatic Encephalopathy (HE) and Chronic Traumatic
Encephalopathy (CTE). HE and CTE are both oxidative stress related diseases that affects the cognitive and behavioral functions,
and the wellness of the brain.
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source,
evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit.
We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while
increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.'s video statement, click here. Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.
FORWARD-LOOKING DISCLAIMER AND DISCLOSURES.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor
created by those sections. This material contains statements about expected future events and/or financial results that are
forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks,
uncertainties. The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or
cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled
Substances Act. The Company does sell and distribute hemp-based products.
CONTACT:
Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P: 888-829-0070
andrew.hard@cmwmedia.com
www.cmwmedia.com
View original content:http://www.prnewswire.com/news-releases/medical-marijuana-inc-portfolio-company-kannalife-sciences-wraps-up-media-tour-discussing-cte-in-new-york-with-new-spokesman-nick-lowery-300528130.html
SOURCE Medical Marijuana, Inc.